Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men

J Clin Endocrinol Metab. 2009 Oct;94(10):3833-41. doi: 10.1210/jc.2009-1275. Epub 2009 Jul 14.

Abstract

Context: With aging, GH, IGF-I, and sex steroid concentrations and glucose tolerance decrease, and body fat and serum lipids increase.

Objective: The aim of the study was to assess GH and/or sex steroid administration effects on serum glucose, insulin, insulin sensitivity, and lipids in older individuals.

Design: A double-masked, 2 x 2 factorial, placebo-controlled, double-dummy design was used for the study.

Intervention: GH and/or sex steroid [transdermal estradiol plus oral medroxyprogesterone acetate in women (HRT); testosterone enanthate (T) in men] were administered for 6 months.

Participants: Healthy, community-dwelling women (n = 57) and men (n = 74) ages 65-88 yr (mean, 72 yr) participated in the study.

Main outcome measures: We measured serum glucose, insulin, and insulin sensitivity [quantitative insulin sensitivity check index (QUICKI) and insulin sensitivity index (ISI)] before and during an oral glucose tolerance test and lipid profiles.

Results: In women, GH did not alter oral glucose tolerance test 120 min or 2-h area under the curve (AUC) glucose values, but it increased 120 min insulin and AUC insulin. There were no significant effects of HRT or GH+HRT. ISI and QUICKI decreased after GH. In men, GH increased 120 min and AUC glucose and insulin AUC. GH+T increased 120 min glucose and glucose and insulin AUCs. T alone did not affect glucose or insulin. ISI decreased after GH and GH+T, whereas QUICKI decreased after GH. GH in women and men and GH+T in men decreased QUICKI by 4 wk. In women, HRT decreased total cholesterol and low-density lipoprotein (LDL)-cholesterol, and GH decreased LDL-cholesterol. In men, total cholesterol decreased after T and GH+T. LDL-cholesterol decreased after GH and GH+T. GH increased serum triglycerides.

Conclusions: GH administration to healthy older individuals for 6 months increased insulin resistance with moderately beneficial effects on lipids.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • Double-Blind Method
  • Estradiol / administration & dosage
  • Estradiol / pharmacology*
  • Estrogen Replacement Therapy
  • Female
  • Gonadal Steroid Hormones / administration & dosage
  • Gonadal Steroid Hormones / metabolism*
  • Gonadal Steroid Hormones / pharmacology
  • Human Growth Hormone / administration & dosage
  • Human Growth Hormone / metabolism*
  • Human Growth Hormone / pharmacology
  • Humans
  • Insulin / blood*
  • Insulin Resistance
  • Lipids / blood*
  • Male
  • Medroxyprogesterone Acetate / administration & dosage
  • Medroxyprogesterone Acetate / pharmacology*
  • Reference Values
  • Testosterone / administration & dosage
  • Testosterone / analogs & derivatives*
  • Testosterone / pharmacology

Substances

  • Blood Glucose
  • Gonadal Steroid Hormones
  • Insulin
  • Lipids
  • Human Growth Hormone
  • Testosterone
  • Estradiol
  • testosterone enanthate
  • Medroxyprogesterone Acetate